Peptibodies fuse bioactive peptides with antibody Fc domains, overcoming peptides' stability and clearance problems while retaining their tissue penetration and target specificity.
2 approved peptibodiesRomiplostim and dulaglutide demonstrate the clinical viability of fusing peptides to antibody Fc domains, with dulaglutide becoming one of the best-selling diabetes drugs worldwide.
What the researchers found
Peptibodies (peptide-Fc fusions) overcome key limitations of therapeutic peptides — including low stability, rapid clearance, and poor absorption — by fusing bioactive peptides to the Fc domain of immunoglobulin. This fusion enhances half-life, stability against proteolytic digestion, and overall efficacy while retaining the peptide's advantages of tissue penetration, cellular internalization, and low immunogenicity. Two peptibodies have achieved regulatory approval: romiplostim (EMA/FDA, for thrombocytopenia) and dulaglutide (FDA, a GLP-1 receptor agonist for type 2 diabetes).
Why it matters
Peptides represent an enormous therapeutic opportunity — they can target pathways that small molecules and antibodies cannot. But their short half-lives and instability have limited clinical success. Peptibodies solve this problem elegantly, and their success (particularly dulaglutide/Trulicity, one of the best-selling diabetes drugs) demonstrates the commercial and clinical viability of this approach. As more peptide targets are discovered, the peptibody platform could enable rapid translation to the clinic.
How the study worked
Narrative review covering the intrinsic properties of therapeutic peptides, the technology and production process for peptibodies, and their therapeutic applications across multiple disease areas.
What this study cannot tell us
As a narrative review, this paper does not present original data. The review primarily focuses on approved peptibodies and those in development, but does not provide a systematic assessment of failure rates or challenges encountered in peptibody development. Manufacturing complexity and cost of Fc fusion proteins compared to simple peptides are acknowledged but not deeply explored.
How to read the evidence
This is a narrative review providing an overview of peptibody technology, production, and applications. It synthesizes existing literature rather than presenting new clinical or experimental data.
When this study was published
Published in 2024, this review captures the current state of peptibody technology during a period of rapid growth in peptide-based therapeutics.
The bigger picture
Peptibodies sit at the convergence of two of the largest drug modality classes — peptides and antibodies. As the peptide drug market grows (projected to exceed $50 billion), engineering platforms like peptibodies that solve peptides' inherent pharmacokinetic limitations become increasingly important. The success of dulaglutide demonstrates that peptibodies can become blockbuster drugs, and the platform is likely to yield more approved therapies in the coming years.
Questions still open
- What peptide-Fc fusion candidates are closest to FDA approval beyond romiplostim and dulaglutide?
- How does the cost of manufacturing peptibodies compare to producing the peptide and antibody separately?
- Could peptibody technology be applied to enhance the stability of emerging therapeutic peptides like BPC-157 or thymosin alpha-1?
Common questions
What is a peptibody and how does it work?
What approved drugs are peptibodies?
Read the original research
Peptibodies: Bridging the gap between peptides and antibodies.
International journal of biological macromolecules, 278(Pt 2), 134718
Citation
Khezri, Hamidhossein; Mostafavi, Mahdiyeh; Dabirmanesh, Bahareh; Khajeh, Khosro. (2024). Peptibodies: Bridging the gap between peptides and antibodies.. International journal of biological macromolecules, 278(Pt 2), 134718. https://doi.org/10.1016/j.ijbiomac.2024.134718